These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 8923123)

  • 21. Pharmacokinetics of milnacipran in renal impairment.
    Puozzo C; Pozet N; Deprez D; Baille P; Ung HL; Zech P
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):280-6. PubMed ID: 9725494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice.
    Massé F; Hascoët M; Bourin M
    Behav Brain Res; 2005 Oct; 164(1):17-28. PubMed ID: 16081166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide.
    Goldberg RJ
    Drugs Aging; 1997 Aug; 11(2):119-31. PubMed ID: 9259175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic optimisation of therapy with newer antidepressants.
    Goodnick PJ
    Clin Pharmacokinet; 1994 Oct; 27(4):307-30. PubMed ID: 7834966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
    Leo RJ; Brooks VL
    Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Milnacipran: a unique antidepressant?
    Kasper S; Pail G
    Neuropsychiatr Dis Treat; 2010 Sep; 6(Suppl I):23-31. PubMed ID: 20856597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine.
    Gervasoni D; Panconi E; Henninot V; Boissard R; Barbagli B; Fort P; Luppi PH
    Pharmacol Biochem Behav; 2002 Oct; 73(3):557-63. PubMed ID: 12151030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.
    Tignol J; Pujol-Domenech J; Chartres JP; Léger JM; Plétan Y; Tonelli I; Tournoux A; Pezous N
    Acta Psychiatr Scand; 1998 Feb; 97(2):157-65. PubMed ID: 9517912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Milnacipran: new preparation. Tricyclics remain first-line antidepressants.
    Prescrire Int; 1998 Apr; 7(34):51-3. PubMed ID: 10183385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
    Sánchez C; Hyttel J
    Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical tolerance of a new antidepressant -- milnacipran].
    Regina W; Vandel P; Vandel S; Sechter D; Bizouard P
    Encephale; 1999; 25(3):252-8. PubMed ID: 10434151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designing a new generation of antidepressant drugs.
    Pinder RM
    Acta Psychiatr Scand Suppl; 1997; 391():7-13. PubMed ID: 9265946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Applications and safety of modern antidepressants in patients with liver diseases].
    Dubarek W; Kucia K
    Wiad Lek; 2007; 60(1-2):28-33. PubMed ID: 17607965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?
    Wong DT; Bymaster FP
    Prog Drug Res; 2002; 58():169-222. PubMed ID: 12079200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reboxetine: a norepinephrine selective reuptake pump inhibitor.
    Preskorn SH
    J Psychiatr Pract; 2004 Jan; 10(1):57-63. PubMed ID: 15334987
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetics of antidepressants: why and how they are relevant to treatment.
    Preskorn SH
    J Clin Psychiatry; 1993 Sep; 54 Suppl():14-34; discussion 55-6. PubMed ID: 8407856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Milnacipran. A review of its use in depression.
    Spencer CM; Wilde MI
    Drugs; 1998 Sep; 56(3):405-27. PubMed ID: 9777315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct effects of the serotonin-noradrenaline reuptake inhibitors milnacipran and venlafaxine on rat pineal monoamines.
    Muneoka K; Kuwagata M; Ogawa T; Shioda S
    Neuroreport; 2015 Jun; 26(9):510-4. PubMed ID: 26016648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.